PCRX - Earnings call transcript Q2 2024 | Pacira BioSciences, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good day, and thank you for standing by. Welcome to the Q2 2024 Pacira BioSciences Earnings Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded.

I would now like to hand the conference over to your speaker today, Susan Mesco, head of Investor Relations. ahead. go Please

Susan Mesco

good to and Welcome today's to Thank our afternoon, second call discuss results. quarter conference you, everyone. XXXX financial

are Medical session. Officer, Executive Chief also here Counsel; Chief Frank question Molloy, is Officer. me and today's Financial Chief Legal Reinhart, and Officer; Slonin, Jonathan for Chief Charlie Joining Tony Lee,

statements let expectations. current begin, that we on remind Before this call based you me will include forward-looking

and Such statements may today represent uncertainties. and of our involve judgment risks as

please factors the For our could the that refer information company, which from to with the available Pacira risk SEC SEC, the concerning filings affect at website. are or

With turn now the Lee. to Frank that, I call will over

Frank Lee

and good Susan, everyone. you, Thank afternoon,

bolstered for the execution you by and clinical that beyond. balance ensure all is of Toward our to to our year the and products, year sales business As objectives. priority and we're half leadership first was and towards meaningful our end, our know, across marked of strong XXXX maintained solid accelerate X our top commercial, ready strengthened team. growth progress We next sheet

culture our modernized market and commercial, organization and our in new talent organization corporate and for capabilities. medical reshaped We access now is a with The place. foundation enhanced

which believe to We remainder that the the XXXX top growth the sustainable to the largely I'll ahead is Looking stage strong product today. beyond. the year, will invest driven we of organization continue in for set focus in EXPAREL, by and line and on be growth

priorities. by walking key through start the XXXX Let's X

To compelling bupivacaine. plus broadening data through access block block, for as lower and Phase selling where at from supported see separate Act implementation second, the nerve by III studies the rollout you, partnerships. sites across receptivity start of price X% all market new patient X block; third, of nerve positive clinical the average days EXPAREL I'll of is XXXX; expanding NOPAIN extremity EXPAREL extremity extremity versus to reimbursement continue EXPAREL lower with nerve superiority in utilization to market that GPO remind demonstrated First, we care. or ASP the a Medicare lower with of X of preparing

These data recently valuable of advance to to for We published our see were rule benefits customers EXPAREL of to the leveraging also promote opioid-sparing a no preliminary in CMS we're policy by reimbursement this tool its in pain. are XXXX. pleased outlined new

with within preparation from for initiatives the believe ample We important drive for the In reimbursement EXPAREL there's given key physicians demonstrating this expanding education communications across the utilization inpatient value we're the settings care We our and believe a care. awareness growth economic advancing NOPAIN, these milestone away powerful To and migration be steady room and where drive of tool will multiple EXPAREL efforts, real-world in we're proposition payers. benefits generating outpatient EXPAREL. market's sparing to will opioid highlight data systems, stakeholders. health

was clinicians impact associated emergency visits, as hospital studies [ Each EXPAREL opioid and among awareness includes campaign ]. progress launched as recently administrators, our drive Make department and length revenue received primary patients a stakeholders, targeting and with our retrospective robust management national of readmission surgeries. is rates. The stay, spine To X reduced patients breast reconstruction pharmacists, hospital we EXPAREL publication education campaign, NOPAIN who did the teams. well with who in real-world study lower Recent colorectal, compare of not. use

of stakeholders a and potential new reimbursement January among speed and these solely is outpatient on insights patient its pain growing groups care. awareness ready preliminary around It on market research, understanding Based in when effect focused and of critical 'XX. key takes up Medicare impact on are indicate ensuring level to no our

integrate new change this out roll gears to continue into systems. we'll to market customers their progresses, seamlessly year expanded access. to reimbursement our the As resources Shifting help

new the Through As in to paving we're through way health be opioid-sparing our and management. pricing forefront XXXB know, participation the can of pain also at these NOPAIN partnerships. the care preferential opportunity systems GPO for afford you pricing programs,

have very a favorable cost on will volumes takes net X up with in to over X%. NOPAIN year sales of plus at only be when effect reimbursed as prior they'll customers EXPAREL partnership, We're which Our acquisition the accounts, continues Premier at dollars. modest and perform now impact post with launch months a ASP expected premier XXXX, our

We're partnership also leveraging additional for opportunities. premier our

topic week, meeting. the their last example, a to of interview team, the discuss leadership For had member I Pacira participate hot Premier with a at membership in to opportunity annual

The on NOPAIN. and to with partnering commitment our discussion focused health systems

around within also NOPAIN awareness Premier opportunities utilize to base. membership the drive We

additional Importantly, opportunities offerings expand X have year partnerships to both expected we this with to go GPO to live access patient similar EXPAREL.

ZILRETTA OA. of that ZILRETTA this only registrational report with If products plan could the half our in opportunity to to Turning X intra-articular iovera, pleased and in for million year. approximately steroid for OA first the with underway administered the approved long-acting sizable ZILRETTA also shoulders. dosing Patient according Phase in and each year. study market injections in both use I'm is first shoulder Shoulder successful, are make represents a solid sales III study performing to

spasticity study also registration for the underway. iovera of treatment is for Our

novel spasticity Given space, lack may the we iovera condition. debilitating afflicted in a offer believe the patients for approach this innovation of significant by

OA provide On for novel codes on brief knee. gene like treatment the product antagonist to the therapy and I'd the PCRX-XXX. or research candidate osteoarthritis IL-XRa, update for I This receptor Interleukin front, a development or of of

study primarily need clinically OA. and from PCRX-XXX is therapies. function reported XX do I the this suffering of modification and OA. in of Phase from function offer not moderate-to-severe improvements patients only results a unmet XX-patient for knee and to the lack encouraging to Earlier injectable modification year, durable X disease single-dose and X million months relieve significant disease the meaningful with for space. to therapies drugs we pain This lack interim OA of and is Current pain due in There the

In This all a was of effect. least PCRX-XXX and of for this at clinically doses year single study, levels meaningful I large across intra-articular severity all observed at X demonstrated Phase sustained injection postinjection. a

well favorable a PCRX-XXX with safety tolerated profile. Importantly, was

We that X our presentation and research follow from were be pain submitted more physicians and by these to meeting for continue scientific market on data board, a years and the for or have Based while patients disease and transformative dose the medical at both now for in patients. considered year fall. improving our a logic potentially modifying function with will single a feedback

for gene therapies that durability unmet clinically systems. pieces on care in traditional a patients the a than more be platform rare adenovirus would address needs of Unlike knee health like year high-capacity Furthermore, of or and to PCRX-XXX focus novel HCAd prevalent OA. leverages economically diseases, and meaningful properties

of durable Importantly, meaningful of support treatment manufacturing delivery our unlock of strategy goods. very by through economically affected will low the and local and therapy enabled large-scale favorable dosing cost to and viable joint, adenovirus potential to provide the gene high-capacity

to our you for meeting next details received We're on or RMAT more the have first ever Medicine month osteoarthritis. RMAT the the may clinical advancement PCRX-XXX therapy recall, to scheduled a future our to As FDA's FDA calls. designation of forward gene sharing Regenerative plans PCRX-XXX in for discuss We first product look with development. Advanced Therapy on

discussion turn that, call litigation. for a over patent EXPAREL of brief to Tony the the I'll With

Anthony Molloy

and the everyone. of touch track the I'll bupivacaine is of in the separate good a IV decision a Paragraph and impact our version still all patent Thanks, Frank, and eVenus, lawsuits you, litigation. briefly steps against generic FDA's To on afternoon, FDA's has pending. multiple are liposomal on infringement recent next approval our which remind no

respect first our case pat. clarity, eVenus May. believe we I That case infringing to through to this lawsuit. could out first on play X XXX concluded patent The We scenarios said, our to involving a is want walk made strong that the that in provide with

Pacira lawsuit the wins January the eVenus the of patent against a Pharmaceutical. generic the Under we court X. until from expiration expect XXX this [indiscernible] XXXX. scenario, launching EVenus would in Outcome

to their approval, ability unless So decision. lower an successfully is eVenus the and no drug they appeal for court's commercialize even FDA overturn with for there

of particular infringing is that Outcome the X. XXX eVenus court patent, that not upholds the validity The on patent. but concludes

for We this being that and underway first the XXX and patents infringement a patents positive lawsuits litigated. than this XXX XXX, Pacira, also patent Three were is given these only broader the additional as are for XXX view our patent. XXX,

In We of our Orange through many to in patents. also forthcoming, of be would expiration January have to patents commercially dates order are which other successful, listed that all XXXX. Book overcome be have will with the eVenus

place depending EXPAREL If court. eVenus have The well this and the Outcome does concludes of X. franchise we findings valid not XXX is from happens, believe ideal the strategy the not patent is We comprehensive directions. in a multiple least protected firmly that scenario. that infringe. This is the on court

the the to business, our steps shareholders, other committed stakeholders. and are necessary taking protect We interest to patients of

the expect trial very first on case opinion We soon. its

sure details we a upon and legal say share have best than believe is position around you eVenus our other that I'm would publicly our patents. we it can be As to not infringing in interest appreciate, strong to our strategy that legal

advancing will event said, investors a That defend with vigorously engage strategy of robust EXPAREL the to decision. are court ready any franchise we our stand the We in legal multifaceted and of we our I and defend being patients, emphasize safety vigorously that clinicians integrity unfolds. informed as want EXPAREL. of intellectual responsibility their process and and other and this our to a we property have a proven stakeholders to keep

Charlie? over I'll now Charlie call report. his the turn for financial to

Charles Reinhart

will we can Tony, along afternoon. of reconciliation update A sales you, to release on and I financial our Thank found margin start issued the in be trends. be these measures good remind non-GAAP and afternoon. GAAP, To this you, news with I'll discussing everyone. afternoon, this an metrics, with description

quarter $XXX.X million XXXX. to Second sales increased million EXPAREL $XXX.X in versus

were January by increase biomix the 'XX in with launch growth price associated the a Premier of and in Volume shift discounting offset partnership. largely

to the million million $X.X second quarter increased of Second sales quarter's ZILRETTA to versus And in in compared iovera $XX.X XXXX. improved $X.X to $XX.X million XXXX. sales million

quarter to driven X to of margin basis, full margins our high percent year products. Turning gross the for end all XX% our of was On consolidated XX%, margin. strong XX% second guided gross a at range non-GAAP by

expense, $XX.X year. from R&D reported to increased second $XX.X quarter million the non-GAAP million For last

OA million shoulder iovera of for activities note, costs, prior included manufacturing from This for $X.X expansion increase second are R&D Of primarily start-up relates studies year. capacity product spasticity. down the quarter development for of the $X.X and million registration which in our and ZILRETTA expense to

Diego Our is pre-commercial Non-GAAP from the production in and $XX.X suite XXX-liter San scale-up up activities second are million commercial began million $XX earlier expense the last now EXPAREL came this year. which in at in SG&A complete month. manufacturing quarter,

including organizations, education This increase to separate that are making ahead due we will and awareness investments consulting our access drive commercial, largely reimbursement of medical Medicare third-party market programs in strategic is services. and and

All of resulted of million. in adjusted quarter another significant of this EBITDA $XX.X

investments, the to million about we million financing, us $XXX.X August that the repurchasing and while and in flow, opportunistically With a to to than completed of significant our have quarter, growth creation, continue successful value $XXX we respect With cash very shareholders which business sheet, by investing second more long-term of returning notes. a retire flexibility convertible allowed the producing our XXXX balance is stock. debt and cash half in to capital

million $XXX year reiterating follows: XX% to $XXX $XX compensation Today, non-GAAP revenue XXXX to of to $XX guidance. million. XX%, R&D SG&A to to million Turning million. of Non-GAAP $XXX we million stock-based $XX of gross million. expense Non-GAAP and guidance million $XX margin total full our $XXX expense to are of as up million

I'll call With to turn back Frank. that, the

Frank Lee

expand position. first closing, management. half the proud which the that In confident of making leadership in Charlie. in will innovation our of I'm position the leadership investments support progress non-opioid will and we've pain you, advancing we're help Thank XXXX, in cement We're made this

With well foundation discussed throughout to for we'll undertaken to the the success. continue we're balance our that leaves earlier for year, ensure long-term open operator, that, the sustainable questions. of positioned growth. for we're us ready efforts call ready work As The have we

Operator

Instructions] [Operator

Markets. Gregory from comes RBC question Renza first of our And Capital

Gregory Renza

just Frank, approval generic July July, early X. bupivacaine kick Great. on liposomal to off the

this Just key could you? you to then that on comment wondering To to our in sort development have a confidence I in certainly your EXPAREL time. at And what your follow-up. of degree if surprising just point evolving ability defend was

Frank Lee

that With to case. thanks I you're with ANDA for Greg. Tony regard the mentioned, think And question, the to the Well, do referencing approval. nothing -- as has our

matter. separate And a that's focus. our that's So

Our confidence hasn't regard case. changed with our to

we Tony our disposal. and And outlined, levels so we as legal multiple have of defense action have at that

unchanged. that's So

Gregory Renza

medical resources, the NOPAIN with just prepare mentioned certainly ability you for affairs. the And to

If be looking applying degree and think we tailwind that is and you on as how some extra receiving about give that could just us quantifying an you what granularity just that update XXXX infrastructure will beyond. through to

Frank Lee

it's Yes, question, a Greg. good

say we're XXXX. that proposed and now But month, X, that right we it's track. back go internal past comments there pleased on very exactly me January And on that expect and preparations expected. through come everything we'd Let as is will some our for are we the to this on. comment see There track rule are

As is the foundation of things. as of commercialization affairs I done medical things side expand our capabilities our access the well in mentioned, market our that all as set terms side we've side, on the on to

see we various on the including not as engage NOPAIN, so had customers there's separate their growing but reimbursement. chance meeting. can the of awareness of at only And to our our mentioned customers, premier I've ASP+X And I call, that a annual

do, So additional to a start. we've some we're got work good but off to

Operator

comes question next Sandler. David Piper from of Our Amsellem

David Amsellem

a So couple just of questions.

the in of Frank, the you position, context that was the did are didn't talking So believe that predecessor this that approval your approvability the your approvable. generic? regarding ahead And filing And first, he what CEO as accepting openly quite that's diligencing of a of was you. surprise view company

happen. I on So wanted had this that you that the get of level that did to your ultimately thoughts surprise

might Secondly, share I'll on you your guess, and how can be eVenus to that capacity get come happen, that I you you that, going for the what talk in happen, Maybe market how hypothetical thoughts. in of does that, preparing the that terms telling will think and our that dynamics not your your to out in saying the that that stop intel extent even into own market you're does it's market, play event but does and the there event a to happen.

Frank Lee

for the question, thanks Well, David.

space. about there I I'm when back. come And you I back So what to one, going let come is first joining me frankly, leader mentioned, a to that pipeline leader also, products in we'll made management Pacira the products, time. remember of think pain just great about only as of lot started, because non-opioid portfolio the line some were the questions number It's add to, continue have Pacira. interesting but in a in a over we not I to

by and only products, about pain we've leadership, when terms see interested you that which supporting take in done in all an the that passage years. also before area, our speaking, that of broadly of past interest X think companies the not therapeutic act leadership And over you NOPAIN but in things the here, broadly we've talked about of the

impressed that's what me. So

say you what to come hard time, sort of take will regard during it's I say With resources diligence. is enough to people I when when can that -- back do. any approvals, to give -- surprising not you What it's and they

legal play this road, going piece actions now and Tony But will down that. others right? the to And be anything leave play is change regard I'm that are forward. it Gap] going that in as at first back will I'll come mentioned, be doesn't the So to with -- [Audio to the in

regard the looked come So to happen models I back to that's to that. speculate and really I very position you've forward. risk. road am remember that. don't of believe IP going on there's to speculating IP, want OneGeneric say. down defend really what we're going strength to would our -- rigorously to I about in our With the at sure, hard but and now our launch OneGeneric It's at various I could --

Operator

from comes Santangelo of question next Jefferies. Glen Our

Glen Santangelo

where and sorry, valid, a for the And we different noninfringed. if the the X not the here. and is the invalidity and curious you way scenario infringed. kind scenario seems outcomes Those Tony, the sure the obvious. invalid scenario bookends, guys positive I'm have of you the appreciating potential infringed or out the I'm but somewhat patent where this -- not and X valid and scenario, scenarios of about laid the positive opposite is outcomes while but I'm Frank, of middle full

scenario term. a in outcome one a paint to And that as in positive Tony, that, vulnerable the somewhat where would might think you position company put near that seem the

to I'm you it's think things sort positive. of that think kind you explore and little why in out wanted bit how so of a and And that more play scenario

Frank Lee

Each that that patents. believe we litigation, Sure. Thank you. of you, XXX on during to infringement the of cases. are X course Glen subsequent meet and the mind the nice case And the X other is Keep the other is the have And patents different. reason just in case. to there's are those there one first behind just

So XXX infringed. the isn't other even we believe that patents infringed, if the are

Glen Santangelo

but the And case court no so docket on understanding for it's my -- patents. currently there's other those that

ultimately it the not vulnerability I'm I looks sure eVenus of sure so of take those what interim, get will launch, be cases to the like and a injunction. in how the long pathway not And I'm heard, could guess, preliminary a potential given

I'm you that in kind you pathway And of bit react stop a scenario. might so curious that just I'll there. how if And explore could and little

Frank Lee

Sure. Well, standard I defined. the mean well is

You harm each again, on the being that of XXX. show XXX believe are and and and a litigated, merits. XXX, the have of And the irreparable to XXX, in likelihood patents we imminent success

injunctive in So these it the on X cases, we other cases most the and be to of court appropriate, going outcome a we not a we on resolved relief, the even play that And it's for outcome, that if marathon have strength cases, a patents is be the We've date in do this would could to opinion. we take this in IP system. we are though again, XXX. cases. always like we event that sprint. out the we behind -- believe for could too, yet depending the believe -- believe in do looked But years any do mixed said trial gotten a haven't Again,

Glen Santangelo

you believe patents if a that's the those PI, And are case? to enough get

Frank Lee

It's believe patents. and we believe to -- strength in opinion. again, that is patents, the we seeing without infringing it's the Again, of the say X eVenus hard these

These So not [Audio Gap] that we a there even is the XXX patents. infringed, is being if finding other

Operator

comes Nachman James. question next from Our of Raymond Gary

Gary Nachman

it broader trial. additional progress on as estimated bit how those the for be some more additional or And yes, that. stronger a And then much would file? you a patent judge do case you So expect Do And down those those think XXX patents XXX. time describe if how us cases, X to follow-up. the more on the for color be road what I might long you and give it same can many then the than be how just what the take is to on, would would patents have

Anthony Molloy

take each order. I'll questions But in these of

give didn't the trial give At case the status other So Magistrate this sometime because for conference, cases. that And out recent -- didn't week. these a come first most was a the expecting schedule to we're

these of cases same patent of are Judge front be Jersey. New a of [ different. is Obviously, for Arleo in District the these the ] judge, claims. you at can't going All get same patents to Each of

same X You for patents can't get claims. the

and claim made EXPAREL from say when So there the is different they stronger I broader and properties XXX-liter process. different of they're

that of each So of other the the they're -- different and confident just what we're learned they're we from product, these just eVenus infringing we've -- from patents.

in now. patent of just it's few additional hard predict happens times there to because right consolidation there's from patents, that prosecuting application to And are applications quite a such. we're And a granting. many lot How

including but we to So say do patents this later additional additional from how anticipate it's be many coming this year. patents several hard to have, family, we

Frank Lee

believe mentioned, case. as is want to, many are a Tony we that take Tony and just really come many mentioned marathon, as There I Gary, first going back other be to is this in are could This years. to this process. earlier, the patents, and

things the marathon, in a can to but of believe we happen, So and and this be these patents. we certainly, a validity expect could of strength years, take lot

Gary Nachman

organization of you NOPAIN? have in how Okay. next just you're think but the might margins what ramp Charlie, guidance what to the the you just more the range were And and starting giving end NOPAIN. then just to should quarter. now, because That's for right helpful. get then, much the And be not the how of year about gross year? ready that do Obviously, talk do implementation of full the expectations do in And at trending on look see place Frank, you you higher our like guidance commercial for rest second

Frank Lee

Gary. that, for Thanks

really on First guidance way with delivered has the of that say the to pleased I'm all, let me date. team

look And looking teams Gary, expect of now NOPAIN early say a earlier deployed question, bit year, been so if we year. will year indication a in some segments towards think, the that about adopt your sometime in what of we have relates the to of as that customers the ramp. what will at now who idea the the By we're provide next a take of the our to perhaps key balance the extent of XXXX little at when as to I end year. time, have, it would clear customers very and certain opposed I later to will to

fact that in growing very think our marries NOPAIN, And that strong ASP+X the contract we about will be I we are along going value proposition. education is pending, a to X with separate the proposition see but and that, mentioned also place about not the that As Medicare GPO only clinical patients. reimbursement and be awareness with for

in the is say relates access. foundation commercial, mind market it as to is short, my So what I'd in that medical set

we as into our engage to really customers to in year. start gives go us going execute way what a to and insight we're that clear about next Now expect

Charles Reinhart

as the than Gary, closer margins non-GAAP this actual to to half margins do would go, of anticipate forward the quarter. I year, for quarter second looking look far first second that as

it, and had quarter didn't this challenges quarter. in see First we those challenges

Operator

Hardik from Parikh Our next JPMorgan. of comes question

Hardik Parikh

wondering share around I you just was more options your do wanted kind question just Just of -- you to I this appreciate have. legal strategy. actually guys what is can't ask

do for of I you Or release? for wanted in after a are to case? the over? the like in you, can each regard subsequent you on cap release. of is get release. ask some injunctive -- there guys X specifically know, appeal let's say, injunctive there X injunctive an you Could patent, that X So to filed Could just kind subsequent theory, sort or XXX

Frank Lee

can practice, You the in this all cases. file mean, for before relief In same injunctive though, I all the is judge.

you You really but file you you as can injunction. many of X these -- need want.

Hardik Parikh

Okay. And of then EXPAREL just kind this of the what rest on of the in GPO broadly X contract, the that you and have going net comments year? guys more on impact Any just could said kind for you live have year. on XQ pricing

Frank Lee

With be GPO, and this, end for we regard will and Thanks for And we 'XX X expect expect reiterate year. Hardik. but signed think, I talk guidance question, into of more go us the this and can positive we net the before, positive Charlie by beyond. the that to about we'll that we on be as comment reiterate we to as

So Charlie.

Charles Reinhart

Our original the GPO X contracts quarter. guidance being roughly signed a included

second are a little The X delayed.

haven't impact little a signing the extent us gives that revenues So them. from not to positive suffered

So signed a in to come projected the gross XX% now, couple in on of net by Xrd basis. points going-forward the the is right is all a range. That's to EXPAREL'S down all, time

build is our that of All models. into

Operator

from Sulewski Securities. Our next question from comes Truist Les

Leszek Sulewski

just up build to perhaps guidance on Charlie, the comments.

your built then kind the conditions capital of end? provided conservatism the sample And then been of market current around level remainder commercial high last perhaps Is have shares. And the year? generic strong the it the question, of expect second, on guidance their we an for my there component strategies of we accelerated the a a eVenus or repurchases kind share to allocation Given maybe has and expect there product? would into of given results, anything is XQ you the could

Charles Reinhart

So and question. talk order, them let Tony I'll eVenus about just take sample I'll in the

we on we're been listen, where did and pleased to and do margins with quarter. We think the do we the needed what top business anticipated line So OpEx. second the we in has on

So Well, Remember work that all us see. didn't it Was thought have year, conservative? the all it original conservative, out we're We'll put ranges. of favorably been. guidance last those that might within well. and guidance

So hanging there's bit of a repurchase. too little around well. Share as that

will back -- started we in did. We're by we to as know, extent and it the the cash sense the opportunistic with and think have convert, flow, makes what we evaluate buying million conjunction when we $XX positive of We cash repurchase you stock worth use already and accordingly.

Frank Lee

question eVenus. Charlie, there's a about

Charles Reinhart

Yes.

So we've the work the to and logistics sample product currently is not to a samples. yet, those ANDA of out get judge received the the magistrate before issue

Operator

of question Needham. Our comes next from Serge Belanger

Serge Belanger

it guess, saw in second quarter. the was one I guess on first the first in August we you the you on as And quarter. I for growth the a to XXX or and ] the do Charlie Judge I -- then believe [ same the secondly, Tony, Arleo volume still what expect decision for Xst? Frank by prior EXPAREL, on X% mentioned

consisting GPO Just whether that And front, EXPAREL curious soft print XX% tissue? procedures that of market in how and then past, overall described compares of or relevant procedures. as it's ex lastly, Premier the growth, the coming the to ortho think you've I on

X other or the if are curious a larger similar Just impact? have would

Frank Lee

turn take go that. a reverse EXPAREL on Tony me about talk let Charlie and then order little a So it bit And tissue. versus and the bit, to volume, ortho little I'll over you soft Premier maybe can after

other to with with also opportunities we're that leverage not their Premier have So how about Premier, only we're NOPAIN. agreement is EXPAREL, how to but pulling opportunities about again, other performing, educate membership and through we now pleased how

market. the as As well, we that over you our discussed would before, as think XX% broadly we of XXXB about think GPOs about program encompass if and other well

to I to of providing And the so year better we're our very up products. by with, happy about say, where would terms customers end going wind the in we're of our access

turn it to let Charlie that, over me So with here.

Charles Reinhart

the far procedures medical data. get as knowing we actual X-X takes months It that sales related to to that that -- as have that are So don't us so quickly. data

the to the now, quarter significant we So change second that have but no the in data tie really trends, there's actions. doesn't

Anthony Molloy

decision Serge, we heard and thank by question. from in us arguments going to she week that's at still not we a have happen. Judge expected Arleo X, you as the have to ] August believe closing expect Yes, told May, decision the that that, us for not court lead would anything [ this to the

Serge Belanger

growth you quarter? EXPAREL in can tell this that's us Charlie, worth what on for

Charles Reinhart

second in XX% Roughly quarter. the

Operator

Barclays. next comes from Our of question Prasad Balaji

Balaji Prasad

And X questions from me.

Firstly, litigation the itself. on

at-risk that on While impacting your assume, the is that launch Frank at-risk fair business CapEx launch I or imagine your it an commercial since the taking being this of might reorganization defense and legal not an going like? two, allocation structure I what to on injunctive can influencing embarked relief against year company of into sought, next against is the a would also understand defense you've over. potential priorities, look thoughts And

Frank Lee

based and so And So the beyond. know build in we capabilities, of to half Balaji, foundation our modernize mentioned our IP, for as in the that our we that we're growth, second you been, we've on year, we're listen, that accelerated growth commercialization, approach access. making we've medical laid ready on executing about what know, market driving sure and we 'XX

I'll what So say that. that's to

not that the generic, all I I'll Again, really terms this that things can't X. X of reiterate could in happen. different speculate is

this So that's we have want to back know. to I go. And other to, fact to relative the to that's the all first litigation still piece come litigated that again, important an patents of is being

a going is it be So marathon. to

X speculate point tactics folks at generic, can to the again, here strategies. all the look there's about sure and not X. really don't I'm kinds I But that. different want So of is

Balaji Prasad

million opportunity Understood, Maybe asked coming quarter, market quick NOPAIN. I follow-up. Last about the within XX just from Frank. a procedures the incremental

to out. you your clarity on incremental this Checking -- in opportunity? the this what team better is was there's exact that now on think I said figuring have

Frank Lee

Difficulty] their can think Yes, -- we of guidance into with the I of in really end the we year, for terms able plans, stick of and teams we to this we're to towards their and team to that. year, granular now are proud as year going thinking, really like I'm to have that provide just be date enhanced engage next guidance [Technical customers Balaji, get as early confidence the get and this

tight, I the as So we're getting is hang foundation mentioned there, set.

and excited second the so feel the And building. I'm actually momentum I half, really about

later. move be we'll to sooner likely kinds customers identify than of as Again, and those so are able And we to rather adopt forward. accounts

So be guidance to growth. on we'll the $-- terms the provide early in based middle or and some adopters of and that, adopters able adopters late

Operator

This would Mesco, now concludes question-and-answer in. back of it the to Head turn like I Investor Relations, to remarks. closing Susan

Susan Mesco

on you, all time for call the and Thank today. and your thanks Judy, to questions

we pave the and be of NOPAIN lie for be year, balance XXXX, will We of are to about The the that well. Throughout mission. a will epidemic success. importance our way for continue which opioid long-term national our Thank for are we the you, believe the the the ensure continues of in vital excited to positioned well us. crisis, underscoring rollout we ahead opportunities

Operator

call. you conference This you concludes and today's for disconnect. Thank participating, may now

Pacira BioSciences (PCRX) 30 Jul 242024 Q2 Earnings call transcript